Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR).
Anna Couvillon
No relevant relationships to disclose
Melony A. Beatson
No relevant relationships to disclose
Nancy Harold
No relevant relationships to disclose
Fatima H. Karzai
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose